Evidence Review
Cognitive Function Trials
Kennedy et al. (2020) — Nutrients [1]
The most rigorous trial to date enrolled 132 healthy adults aged 35–65 in a 29-day, double-blind, placebo-controlled study. Participants received 430 mg, 860 mg, or 1,290 mg/day of wild green oat extract (Neuravena). Cognitive testing at baseline, day 15, and day 29 used the Computerized Multi-Tasking Test (CMT) and the Spatial Working Memory (SWM) test.
Both the 430 mg and 1,290 mg doses significantly improved SWM performance after 29 days. The 1,290 mg dose also reduced electrodermal activity (a physiological stress marker) during the stressor condition. Single-dose testing on day 1 at 1,290 mg showed immediate improvements in multitasking performance. The 860 mg dose was the least consistently effective across outcomes — a non-linear dose-response pattern noted by the authors. No adverse events were reported.
Kennedy et al. (2017) — Nutritional Neuroscience [2]
This within-subjects crossover trial tested a single 1,600 mg dose of wild green oat extract in middle-aged adults. Using an objective computerized cognitive battery (COMPASS), participants showed significant improvements in attention and spatial working memory at 2.5 and 4 hours post-dose compared to placebo. The authors noted that cognitive improvements were most pronounced on accuracy measures (not speed), consistent with a PDE4-mediated mechanism that improves signal quality rather than processing rate.
Stress and Wellness
Friling et al. (2024) — Frontiers in Nutrition [3]
A randomized, double-blind, placebo-controlled trial enrolled 145 adults (mean age 44) attempting to cut smoking. Participants received 900 mg/day Neuravena or placebo for 8 weeks, with a 4-week follow-up. The primary endpoint was smoking reduction, but secondary health outcomes were extensively measured.
The supplement group showed significantly lower perceived stress (PSS scale) and improved Pittsburgh Sleep Quality Index scores compared to placebo at weeks 4 and 8. Benefits persisted 4 weeks after discontinuation. The smoking cessation endpoint also favored supplementation (66.7% vs. 49.3% achieved ≥20% reduction, p=0.034). No serious adverse events were reported. Limitations include the smoking-cessation context potentially confounding the stress outcomes.
Cardiovascular Evidence
Llanaj et al. (2022) — European Journal of Nutrition [4]
This systematic review and meta-analysis covered 74 RCTs (4,937 participants) examining Avena sativa supplementation on cardiovascular disease risk markers. Most trials used dietary oat interventions, not isolated oat straw extract.
Pooled effect sizes: total cholesterol −0.42 mmol/L (95% CI −0.51 to −0.34), LDL −0.29 mmol/L (95% CI −0.37 to −0.21), fasting glucose −0.25 mmol/L (95% CI −0.45 to −0.06), body weight −0.94 kg (95% CI −1.37 to −0.50), and waist circumference −1.06 cm (95% CI −2.00 to −0.13). The effects were driven primarily by beta-glucan content. Blood pressure and inflammatory marker responses were less consistent. The authors flagged risk of bias concerns in 81.1% of included trials.
Mechanistic Studies
Sur et al. (2008) — Archives of Dermatological Research [5]
This in vitro and ex vivo study established the anti-inflammatory mechanism of oat avenanthramides. At concentrations as low as 1 part per billion, avenanthramides inhibited IκB-α degradation in human keratinocytes — blocking NF-κB pathway activation and downstream TNF-α and IL-8 expression. These are the same inflammatory mediators implicated in metabolic and cardiovascular disease. The study used cell culture and skin explant models; clinical translation of these concentrations requires further in vivo study.
Nie et al. (2006) — Atherosclerosis [6]
Using rat and human vascular smooth muscle cells, this study found that avenanthramide-2c suppressed cell proliferation by 41–73% and increased nitric oxide production up to ninefold in endothelial cells at 120 μM. The mechanism involved upregulation of endothelial nitric oxide synthase (eNOS). Smooth muscle cell proliferation is a key early event in atherosclerotic plaque formation; the dual effect of reducing proliferation and increasing vasodilatory NO represents a theoretically meaningful cardiovascular benefit. However, these are in vitro data and the concentrations used exceed what is readily achieved through supplementation.
Strength of Evidence Summary
The cognitive data are among the stronger findings in the herbal nootropics literature: multiple independent randomized controlled trials, objective cognitive endpoints, and a coherent mechanistic explanation. Effect sizes are modest but consistent. The stress and sleep benefits from the 2024 trial are promising but come from a single study conducted in a specific population.
The cardiovascular case is more complex. Meta-analysis evidence is robust for dietary oat consumption reducing LDL, but it largely reflects beta-glucan effects. The avenanthramide vascular findings are mechanistically compelling but currently rest on cell culture data. Human trials specifically testing oat straw extract on cardiovascular biomarkers are lacking. Overall this is a supplement with a credible evidence base for cognition and stress, with cardiovascular benefits that are biologically plausible but not yet confirmed in trials using the supplement form.